CIBC Bancorp USA
NKTR icon

CIBC Bancorp USA’s Nektar Therapeutics NKTR Stock Holding History

CIBC Bancorp USA’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$974K Buy
16,085
+12,189
+313% +$856K ﹤0.01% 1118
2026
Q2 		$272K Buy
+3,896
New +$285K ﹤0.01% 1592

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Prosight Management
Prosight Management Dallas, Texas $515M AUM 2.95% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

CIBC Bancorp USA's NKTR Position: Q3 2026 in Review

CIBC Bancorp USA increased its Nektar Therapeutics (NKTR) stake by 313% in Q3 2026, buying an estimated $856K and bringing the position to 16,085 shares worth $974K. The position accounts for ﹤0.01% of the portfolio, ranked #1118.

CIBC Bancorp USA first reported a position in NKTR in Q2 2026 and has held it in 2 quarters since. 168 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • CIBC Bancorp USA held 16,085 shares of Nektar Therapeutics worth $974K as of Q3 2026.
  • CIBC Bancorp USA bought 12,189 Nektar Therapeutics shares in Q3 2026, an estimated $856K.
  • Nektar Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1118 holding.
  • CIBC Bancorp USA first reported a position in Nektar Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 168 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.